Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +447.83% and +974.37%, respectively, for the quarter ...

Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027- ...

A Victorian keeper's house in Oregon, two beach cottages on a Puget Sound island, and a lighthouse inn in San Francisco Bay ...

Collaboration revenue increased to $83.5 million from $8.2 million a year earlier. The $75.4 million increase primarily reflected a $74.1 million cumulative catch-up adjustment related to updated ...

The sixth edition of Pitchfork Festival London was the biggest it's ever been. For six days, nearly 100 artists performed ...

Foghorn Therapeutics Inc. (FHTX) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2026. This widely-known ...

Foghorn Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported net income was USD 58.15 million ...

NEW YORK CITY, NY / ACCESS Newswire /, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Foghorn ...

WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE)-- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines against challenging targets in oncology and ...

Half of the 52 companies sent no welcome or basket email in 30 days. Smith Optics scored top, and just three used press or ...

The new film from Warner Bros. Animation is the first theatrically released "Looney Tunes" short in over a decade.

The fair value estimate for Foghorn Therapeutics has been reset from US$6.00 to about US$4.17, reflecting a meaningful change in how the stock is currently modeled. This move lines up with recent ...